298 related articles for article (PubMed ID: 14617792)
21. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
Fang G; Chang BS; Kim CN; Perkins C; Thompson CB; Bhalla KN
Cancer Res; 1998 Aug; 58(15):3202-8. PubMed ID: 9699642
[TBL] [Abstract][Full Text] [Related]
22. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
23. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.
Alas S; Bonavida B
Cancer Res; 2001 Jul; 61(13):5137-44. PubMed ID: 11431352
[TBL] [Abstract][Full Text] [Related]
24. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
25. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
[TBL] [Abstract][Full Text] [Related]
26. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
27. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
[TBL] [Abstract][Full Text] [Related]
28. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
29. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells.
Ibrado AM; Liu L; Bhalla K
Cancer Res; 1997 Mar; 57(6):1109-15. PubMed ID: 9067280
[TBL] [Abstract][Full Text] [Related]
30. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent.
Burek M; Maddika S; Burek CJ; Daniel PT; Schulze-Osthoff K; Los M
Oncogene; 2006 Apr; 25(15):2213-22. PubMed ID: 16288204
[TBL] [Abstract][Full Text] [Related]
31. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine.
Emmanouilides C; Jazirehi AR; Bonavida B
Cancer Biother Radiopharm; 2002 Dec; 17(6):621-30. PubMed ID: 12537665
[TBL] [Abstract][Full Text] [Related]
32. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.
Zhang N; Khawli LA; Hu P; Epstein AL
Clin Cancer Res; 2005 Aug; 11(16):5971-80. PubMed ID: 16115941
[TBL] [Abstract][Full Text] [Related]
33. Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells.
Chipuk JE; Bhat M; Hsing AY; Ma J; Danielpour D
J Biol Chem; 2001 Jul; 276(28):26614-21. PubMed ID: 11320089
[TBL] [Abstract][Full Text] [Related]
34. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells.
Perkins C; Kim CN; Fang G; Bhalla KN
Cancer Res; 1998 Oct; 58(20):4561-6. PubMed ID: 9788601
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
Mathas S; Rickers A; Bommert K; Dörken B; Mapara MY
Cancer Res; 2000 Dec; 60(24):7170-6. PubMed ID: 11156427
[TBL] [Abstract][Full Text] [Related]
37. Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
Li ZM; Jiang WQ; Zhu ZY; Zhu XF; Zhou JM; Liu ZC; Yang DJ; Guang ZZ
Cancer Biol Ther; 2008 Jan; 7(1):51-60. PubMed ID: 17938578
[TBL] [Abstract][Full Text] [Related]
38. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
Byrd JC; Kitada S; Flinn IW; Aron JL; Pearson M; Lucas D; Reed JC
Blood; 2002 Feb; 99(3):1038-43. PubMed ID: 11807010
[TBL] [Abstract][Full Text] [Related]
39. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl.
Anto RJ; Mukhopadhyay A; Denning K; Aggarwal BB
Carcinogenesis; 2002 Jan; 23(1):143-50. PubMed ID: 11756235
[TBL] [Abstract][Full Text] [Related]
40. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
Smith MR; Joshi I; Jin F; Obasaju C
BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]